Regeneron Pharma (REGN) PT Raised to $669 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini raised the price target on Regeneron Pharma (NASDAQ: REGN) to $669.00 while maintaining an Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
